Chand Nair, MD
Psychiatry · Fort Washington, PANPI 1164453775
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,135 of the $36,857 with a category attached, or 79.0%. Alkermes, Inc. accounts for 71.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $24,143 and has fallen 98.1% since, to $459 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $234.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$26K
- Johnson & Johnson$7K
- Idorsia Pharmaceuticals US Inc$1K
- Otsuka America Pharmaceutical, Inc.$686
- Sunovion Pharmaceuticals Inc.$601
- Teva Pharmaceuticals USA, Inc.$238
- plus $508 from 7 others
What the payments were for
- Speaking & faculty fees$29,13579%
- Travel & lodging$3,51910%
- Food & beverage$4,20311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 40 | $26,170 |
| Johnson & Johnson | 57 | $7,465 |
| Idorsia Pharmaceuticals US Inc | 1 | $1,190 |
| Otsuka America Pharmaceutical, Inc. | 28 | $686 |
| Sunovion Pharmaceuticals Inc. | 10 | $601 |
| Teva Pharmaceuticals USA, Inc. | 3 | $238 |
| Neurocrine Biosciences, Inc. | 5 | $179 |
| E.r. Squibb & Sons, L.L.C. | 3 | $132 |
| AbbVie(2 entities) | 4 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Indivior Inc. | 2 | $52 |
| Validus Pharmaceuticals LLC | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$99,823
- ARISTADA INITIO$24,956
- SPRAVATO$6,155
- LYBALVI$3,160
- QUVIVIQ$1,190
- LATUDA$420
- UZEDY$222
- ABILIFY MAINTENA$116
- REXULTI$104
- INVEGA SUSTENNA$103
- INGREZZA$103
How this compares
$36,857 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 16 | $177 |
| Omeprazole | 16 | $84 |
| Levothyroxine Sodium | 12 | $82 |
| Trazodone Hcl | 15 | $68 |
| Fluoxetine Hcl | 11 | $49 |
| Alendronate Sodium | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Fort Washington
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.